

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7943650

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SHANDONG LUYE PHARMACEUTICAL CO., LTD.	04/26/2023
NANJING LUYE PHARMACEUTICAL CO., LTD.	04/24/2023
RECEIVING PARTY DATA	
Name:	GENEORA PHARMA (SHIJIAZHUANG) CO., LTD.
Street Address:	5TH FLOOR, RUNJIANG HEADQUARTERS INTERNATIONAL BUILDING, NO. 455 YUHUA EAST ROAD
Internal Address:	SHIJIAZHUANG HIGH-TECH ZONE
City:	SHIJIAZHUANG CITY, HEBEI PROVINCE
State/Country:	CHINA
Postal Code:	050000
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9532991
CORRESPONDENCE DATA	
Fax Number:	(609)799-7655
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	609-799-7600
Email:	jeffrey.liao@luye.com
Correspondent Name:	JEFFREY ZHI YANG LIAO
Address Line 1:	502 CARNEGIE CENTER DRIVE, SUITE 100
Address Line 4:	PRINCETON, NEW JERSEY 08540
ATTORNEY DOCKET NUMBER:	06624-P0004B
NAME OF SUBMITTER:	JEFFREY ZHI YANG LIAO
SIGNATURE:	/Jeffrey Zhi Yang Liao/
DATE SIGNED:	05/09/2023
Total Attachments: 4	
source=02. LY03004 US9532991 Patent Assignment - Shandong Luye to Jiaao#page1.tif	
source=02. LY03004 US9532991 Patent Assignment - Shandong Luye to Jiaao#page2.tif	
source=02. LY03004 US9532991 Patent Assignment - Shandong Luye to Jiaao#page3.tif	

PATENT ASSIGNMENT

WHEREAS, Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, and Youxin Li, the inventors (the "Inventors"), have made certain inventions or discoveries (or both) as set forth in Letters Patent of the United States of America, entitled RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION bearing U.S. Patent No. 9,532,991 issued on January 3, 2017 (the "Patent");

WHEREAS, Shandong Luye Pharmaceutical Co., Ltd., a limited liability company organized and existing under the laws of the People's Republic of China ("China"), and having a principal place of business at No. 15, Chuangye Road, High-Tech Zone, Yantai, Shandong Province, 264670, China, and together with its successors and assigns, hereinafter called "Shandong Luye", had acquired the entire right, title and interest in and to the Patent from the Inventors as reflected in a Patent Assignment recorded in the United States Patent and Trademark Office at Reel/Frame: 039245/0182,

WHEREAS, Shandong Luye assigned the entire right, title and interest in and to the Patent to Shandong Luye and Nanjing Luye Pharmaceutical Co., Ltd., a limited liability company organized and existing under the laws of China, and having a principal place of business at No. 28, Gaoxin Road, Nanjing Hightech Industrial Development Zone, Nanjing, Jiangsu Province, 210061, China, and together with its successors and assigns, hereinafter called "Nanjing Luye", as reflected in a Patent Assignment recorded in the United States Patent and Trademark Office at Reel/Frame: 040339/0916 (and corrected as to the Zip Code only for Shandong Luye at Reel/Frame: 047642/0608),

WHEREAS, Shandong Luye and Nanjing Luye (collectively, as co-owners of the Patent, hereinafter called "Assignors") are willing to transfer such right, title and interest to Assignee (as hereinafter defined);

WHEREAS, Geneora Pharma (Shijiazhuang) Co., Ltd., a corporation organized under the laws of China, with a principal place of business at 5th Floor, Runjiang Headquarters International Building, No. 455 Yuhua East Road, Shijiazhuang High-Tech Zone, Shijiazhuang City, Hebei Province, 050000, China ("Geneora"), and, together with its successors and assigns, hereinafter called "Assignee", is desirous of acquiring the title, rights, benefits and privileges hereinafter recited;

NOW THEREFORE, for valuable consideration furnished by Assignee, the receipt and sufficiency of which is hereby acknowledged, Assignors hereby, without reservation:

1. Assign, transfer and convey to Assignee the entire right, title and interest in and to said inventions and discoveries, said Letters Patent of the United States of America, any and all other applications for Letters Patent on said inventions and discoveries in any and all countries, including all PCT, national stage, non-provisional, continuation, divisional, reissue, renewal, and substitute applications based in whole or in part upon said inventions or discoveries, or upon said applications, and any and all Letters Patent, reissues and extensions of Letters Patent granted for said inventions and discoveries or upon said

applications, and every priority right that is or may be predicated upon or arise from said inventions, said discoveries, said applications and said Letters Patent;

2. Authorize Assignee to file patent applications in any or all countries and jurisdictions on any or all of said inventions and discoveries in their names or in the name of Assignee or otherwise as Assignee may deem advisable, under the Patent Cooperation Treaty, European Patent Convention, the laws of any country or jurisdiction, or otherwise;

3. Authorize and request the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue or transfer all said Letters Patents to Assignee, as Assignee of the entire right, title and interest therein or otherwise as Assignee may direct;

4. Warrant that they have not knowingly conveyed to others any right in said inventions, discoveries, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing any of said inventions or discoveries; and that they have good right to assign the same to Assignee without any encumbrances;

5. Bind their legal representatives and assigns, as well as themselves, to perform, upon Assignee's request and at Assignee's expense, but without additional consideration to them, all acts reasonably serving to assure that said inventions and discoveries, said patent applications and said Letters Patent shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by them, their legal representatives and assigns as if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents, including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known to them relating to said inventions and discoveries or the history thereof; and to furnish Assignee with any and all documents, photographs, models, samples and other physical exhibits in their control or in the control of their heirs, legal representatives or assigns, which may be useful for establishing the facts of the conceptions, disclosures, and reduction to practice of said inventions and discoveries.

IN WITNESS WHEREOF, Shandong Luye Pharmaceutical Co., Ltd. and Nanjing Luye Pharmaceutical Co., Ltd., through their authorized representatives, have hereunto set their hands and signed their names.

[The rest of this page is left intentionally blank.]

2023.04.26
Date
Lifang Sun (Assignor)
Shandong Luye Pharmaceutical Co., Ltd.
By: Lifang Sun
Title: Vice President of Intellectual Property
Department

I declare that I was personally present and did see Lifang Sun, who is personally known to me to be the Vice President of the Intellectual Property Department of Shandong Luye Pharmaceutical Co., Ltd., duly sign and execute the same.

Date 2023.04.26 Signed at Yantai, China
Qingjing Xu
(Name of Witness) Qingjing Xu
(Signature of Witness)

ACCEPTED:

Geneora Pharma (Shijiazhuang) Co., Ltd.

2023.04.27
Date
Shixu Li (Assignee)
(Signatory Signature)
Shixu Li
General Manager
(Assignee Signatory Name, Title)

I declare that I was personally present and did see Shixu Li, who is personally known to me to be the General Manager of Geneora Pharma (Shijiazhuang) Co., Ltd., duly sign and execute the same.

Date 2023.04.27 Signed at Yantai, China
Xuejie Li
(Name of Witness) Xuejie Li
(Signature of Witness)

2023. 04. 24
Date

Guangjun Qiao (Assignor)
Nanjing Luye Pharmaceutical Co., Ltd.
By: Guangjun Qiao
Title: General Manager

I declare that I was personally present and did see Guangjun Qiao, who is personally known to me to be the General Manager of Nanjing Luye Pharmaceutical Co., Ltd., duly sign and execute the same.

Date 2023. 04. 24

Signed at Nanjing, China

Xian Yang
(Name of Witness)

Xian Yang
(Signature of Witness)

ACCEPTED:

Geneora Pharma (Shijiazhuang) Co., Ltd.

2023. 04. 27
Date

Shixu Li (Assignee)
(Signatory Signature)

Shixu Li
General Manager

(Assignee Signatory Name, Title)

I declare that I was personally present and did see Shixu Li, who is personally known to me to be the General Manager of Geneora Pharma (Shijiazhuang) Co., Ltd., duly sign and execute the same.

Date 2023. 04. 27

Signed at Yantai, China

Xuejie Li
(Name of Witness)

Xuejie Li
(Signature of Witness)